Skip to main content
Clinical Trials/ISRCTN46173989
ISRCTN46173989Completed未知

Combination drug treatment in moderate-to-severe essential hypertension

Department of Health0 sites20 target enrollmentStarted: September 30, 2005Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • Patients with uncomplicated, moderate-to-severe essential hypertension which is not adequately controlled on triple therapy with amlodipine 5-10 mg once daily (o.d.), enalapril 10-20 mg b.d. and bendrofluazide 5 mg o.d., iv)

Exclusion Criteria

  • Malignant or accelerated hypertension. Serum creatinine >60umol/L, ischaemic heart disease, cerebrovascular disease, impaired liver function, diabetes mellitus, pregnancy or risk of pregnancy, lactation, history of alcoholism, drug abuse or other problems likely to invalidate the informed consent.

Investigators

Similar Trials